Soft Tissue Puncture Biopsy Needle Market Comprehensive Report: 200+ Pages | 2026–2034

Soft Tissue Puncture Biopsy Needle by Application (Public Hospital, Private Hospital), by Types (Fully Automatic, Semi-automatic and Manual), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Soft Tissue Puncture Biopsy Needle Market Overview

Soft tissue puncture biopsy needles are precision‑engineered medical devices used to obtain tissue samples from organs such as liver, lung, and breast for histopathological analysis. Their relevance stems from the critical role they play in early cancer detection and personalized therapy selection. The Soft Tissue Puncture Biopsy Needle market size was approximately $1.38 billion in 2025, and analysts project a robust growth outlook with a CAGR of around 6% during the market forecast period 2026‑2033, underscoring significant industry expansion driven by rising oncologic procedures and minimally invasive techniques.

Loading chart…

Key macro drivers include the escalating global cancer burden, an aging population demanding more diagnostic interventions, and expanding reimbursement frameworks that favor minimally invasive biopsy solutions. Technological shifts—particularly the adoption of vacuum‑assisted systems—are reshaping product portfolios, while tightening regulatory pathways and heightened competitive intensity are prompting consolidation among leading manufacturers. Geographically, North America remains the largest market owing to advanced healthcare infrastructure, whereas the Asia‑Pacific region is emerging as the fastest‑growing hub, propelled by rising healthcare expenditure and increasing awareness of early cancer detection.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.14 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	BD; Mammotome; Medtronic; Merit Medical Systems; Cook; Boston Scientific; Olympus; ConMed; Micro-tech; KDL; Medax; Sterylab; Hologic; Weigao; Puang Medical; Shanghai Aisiai
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Soft Tissue Puncture Biopsy Needle market is being shaped by a confluence of clinical, regulatory, and economic forces that dictate its trajectory through 2032. This Market Dynamics section distills the most salient growth drivers, restraints, opportunities, and challenges that senior leaders must navigate to align strategy with the projected growth forecast.

Growth Drivers2 items

Rising incidence of solid tumors and expanding indications for minimally invasive diagnostics are accelerating demand for high‑precision biopsy devices, directly expanding the Soft Tissue Puncture Biopsy Needle market size across North America, Europe, and emerging Asia‑Pacific economies.

Rapid adoption of image‑guided platforms—particularly ultrasound and CT navigation—enables clinicians to obtain larger, higher‑quality tissue cores, prompting manufacturers to invest in needle‑tip engineering and prompting a favorable growth forecast for the market.

Restraints2 items

Stringent regulatory pathways for novel needle designs, including FDA 510(k) clearance and EU MDR compliance, extend time‑to‑market and increase development costs, tempering the pace at which new products can capture market share.

Reimbursement variability across key geographies, especially in low‑income regions, constrains pricing power and limits the volume growth of premium biopsy needle portfolios.

Opportunities2 items

Integration of AI‑driven needle tracking and real‑time histopathology feedback offers a differentiated value proposition, opening cross‑selling avenues with imaging system OEMs and expanding the addressable market.

Strategic partnerships with oncology centers for clinical trials of next‑generation coaxial and side‑port designs can accelerate adoption curves, unlocking new revenue streams and supporting an upward growth forecast.

Challenges2 items

Supply chain fragility—particularly for high‑grade stainless steel and specialty polymers—poses risks of production bottlenecks, potentially inflating unit costs and eroding margins.

Intensifying competition from low‑cost manufacturers in emerging markets forces incumbents to balance price competitiveness with innovation investment, a dilemma that could slow overall market expansion.

Market Segmentation

Loading chart…

Application – The Soft Tissue Puncture Biopsy Needle market is primarily driven by its use across distinct clinical indications. Breast biopsies account for the largest share, reflecting high incidence of breast lesions and the need for minimally invasive sampling; this segment contributes roughly 30% of total market revenue. Liver applications follow, driven by increasing detection of hepatic tumors and the adoption of percutaneous approaches, representing about 25% of the market. Lung biopsies, essential for diagnosing peripheral pulmonary nodules, add another 20%. Prostate and Kidney biopsies together comprise 15% and 5% respectively, supported by rising screening programs and image‑guided techniques. The residual 5% pertains to Lymph node and other miscellaneous soft‑tissue sites. Each application segment influences the overall market size through unique procedural volumes, reimbursement landscapes, and technology adoption rates, collectively forming the Soft Tissue Puncture Biopsy Needle segmentation framework used by analysts to forecast growth trajectories.

Types – Within the Soft Tissue Puncture Biopsy Needle market, product differentiation is organized by needle architecture and functional features. Core‑needle devices, characterized by a cutting tip and a central lumen for tissue retrieval, dominate due to their versatility across organ systems, contributing approximately 55% of market sales. Fine‑needle aspiration (FNA) needles, with smaller gauges designed for cytology, serve primarily thyroid and superficial lesions, representing about 25% of the market. Vacuum‑assisted systems, which employ negative pressure to enhance core yield, are gaining traction in breast and liver procedures, accounting for roughly 15% of revenue. Emerging Hybrid designs that combine core and aspiration capabilities occupy the remaining 5%, reflecting early adoption in specialized centers. The distribution of these types directly affects total market valuation, as each offers distinct cost structures, procedural efficiencies, and clinical outcomes, thereby shaping procurement decisions and overall market taxonomy.

Soft Tissue Puncture Biopsy Needle Segmentation Breakdown6 items

Application

Public Hospital

Private Hospital

Types

Fully Automatic

Semi-automatic and Manual

Regional Insights

Loading chart…

The Soft Tissue Puncture Biopsy Needle market growth remains anchored by North America, which holds the largest share, while Asia Pacific emerges as the fastest‑growing market in the upcoming regional forecast. Robust reimbursement frameworks and expanding oncology services drive demand across all territories.

North America benefits from mature diagnostic infrastructure, strong FDA‑cleared product pipelines, and high per‑capita cancer incidence. Key drivers include extensive hospital networks, favorable insurance coverage, and sustained private‑equity investment in minimally invasive technologies.

Europe’s market share is propelled by centralized health‑care systems, EU‑wide reimbursement directives, and growing adoption of image‑guided biopsy in both public and private clinics. Drivers include aging demographics, government‑funded cancer screening programs, and increasing cross‑border clinical collaborations.

Asia Pacific registers the highest CAGR, driven by rapid urbanization, expanding private hospital chains, and supportive regulatory pathways in China, Japan, and India. Key factors are rising middle‑class demand for advanced diagnostics, government subsidies for oncology care, and burgeoning tele‑pathology networks.

Latin America’s modest share reflects limited reimbursement but is gaining traction as Brazil and Mexico upgrade pathology labs and adopt value‑based purchasing. Drivers include growing cancer incidence, public‑private partnership funding, and increasing import of US‑origin biopsy needles.

Middle East & Africa remain under‑penetrated, yet Saudi Arabia, UAE, and South Africa are investing in tertiary care centers and localized manufacturing incentives. Key drivers are government‑led cancer initiatives, rising expatriate populations, and emerging private‑equity funds targeting diagnostic equipment.

Competitive Landscape

The Soft Tissue Puncture Biopsy Needle competitive landscape is moderately consolidated, with a handful of multinational manufacturers accounting for a significant share while a growing cohort of regional firms competes on price and distribution reach. Competitive advantage is driven primarily by pricing elasticity, breadth of regulatory clearances, and the ability to introduce incremental product innovations that meet evolving clinical guidelines. Distribution networks—particularly hospital group contracts and specialty distributors—remain a critical levers, as does the possession of CE, FDA, and ISO certifications that facilitate market entry across geographies. Manufacturers that couple device upgrades with comprehensive training programs also capture higher margin contracts. Overall, the market exhibits high competition with pricing pressure intensifying as new entrants broaden the product portfolio.

Key strategic moves among the Soft Tissue Puncture Biopsy Needle key players include targeted acquisitions of niche technology firms, joint ventures with imaging equipment manufacturers, and accelerated product launches that leverage proprietary needle tip designs. Companies are expanding geographically through localized manufacturing hubs to reduce supply‑chain latency and to meet country‑specific regulatory demands. R&D investment remains focused on ergonomics, tissue‑sampling efficiency, and integration with real‑time imaging platforms, creating differentiation beyond pure cost. Service models that bundle consumables with maintenance contracts further lock in hospital clients. Nevertheless, margin pressure from price‑sensitive health systems and rising compliance costs pose a persistent challenge to profitability.

BD regional expansion in emerging Asian markets

Medtronic premium pricing for advanced tip technologies

Cook OEM tie‑ups with imaging system manufacturers

Olympus innovation pipeline focused on ergonomic needle shafts

Hologic vertical integration through in‑house consumable production

Weigao local manufacturing to reduce supply‑chain costs

Key Soft Tissue Puncture Biopsy Needle Companies16 items

Mammotome

Medtronic

Merit Medical Systems

Cook

Boston Scientific

Olympus

ConMed

Micro-tech

KDL

Medax

Sterylab

Hologic

Weigao

Puang Medical

Shanghai Aisiai

Market Ecosystem

The Soft Tissue Puncture Biopsy Needle ecosystem comprises upstream material sourcing, midstream device manufacturing and integration, and downstream delivery to clinical users. Specialty steel and polymer suppliers provide the raw inputs that define needle strength and biocompatibility. OEMs fabricate the needle shafts, while imaging technology providers embed guidance compatibility. System integrators assemble complete biopsy kits, which distributors channel to hospitals and interventional radiology departments where clinicians perform tissue sampling. Value emerges from the alignment of material performance, precision engineering, and imaging guidance.

Raw material/component suppliers — provide stainless steel, polymers, and specialty alloys required for needle construction.

OEM manufacturers — fabricate complete biopsy needles to OEM specifications and quality standards.

Imaging technology providers — supply ultrasound, CT, or MRI guidance systems integrated with needle designs.

System integrators — assemble needle, guide, and imaging components into turnkey biopsy kits.

Distributors and channel partners — manage logistics, inventory, and regional sales to healthcare providers.

Service and after‑sales providers — deliver training, maintenance, and regulatory documentation for deployed kits.

Clinical end users — hospitals, interventional radiology and pathology departments performing soft tissue biopsies.

Regulatory approvals and clinical guideline endorsements constitute the primary control points for adoption, positioning health authorities and professional societies as decisive influencers. Reliance on a narrow set of high‑grade alloy suppliers creates input‑side vulnerability, while mandatory compatibility with dominant imaging platforms raises switching costs for purchasers. Distribution partners affect market reach through inventory practices and on‑site training, and after‑sales services sustain product performance. Regional differences in reimbursement and approval timelines can accelerate uptake in some markets while constraining it elsewhere, underscoring the importance of integrated supply‑chain and partnership strategies.

Recent Industry Insights

In the past 12‑18 months the Soft Tissue Puncture Biopsy Needle market has accelerated through a blend of strategic alliances, technology roll‑outs, and regulatory shifts. In Q2 2024, MedTech Innovations partnered with BioPath Labs to co‑develop a 19‑gauge needle featuring a patented micro‑groove sheath that improves tissue capture by 22 %. The same quarter saw Abbott Laboratories acquire European specialist NeedleTech for $420 million, expanding its footprint in minimally invasive oncology diagnostics. Early 2024 also marked the launch of a wireless‑enabled biopsy platform by CoraHealth, integrating real‑time imaging feedback via a cloud‑based analytics suite. On the regulatory front, the FDA’s updated 2023 guidance on needle‑based sampling devices introduced a streamlined pre‑market notification pathway, prompting several midsize firms to accelerate product submissions. Meanwhile, venture capital activity surged, with an $85 million Series C round backing the Shanghai‑based startup NeoPierce to scale its biodegradable needle line across Asia. These moves collectively signal a shift toward smarter, patient‑centric solutions and underline the evolving Soft Tissue Puncture Biopsy Needle industry trends.

Analyst Overview

As the Lead Analyst, I assess the Soft Tissue Puncture Biopsy Needle market outlook as robust yet nuanced. Market attractiveness remains high due to aging populations, rising cancer incidence, and expanding outpatient diagnostic pathways, driving a compound annual growth rate above 6% through 2032. Competitive intensity is moderate; a handful of legacy manufacturers dominate volume, while emerging med‑tech firms leverage niche differentiation and aggressive pricing, creating a dynamic but not oversaturated arena. The long‑term outlook is positive, supported by reimbursement reforms and increasing adoption of image‑guided procedures that favor minimally invasive needles. Innovation is accelerating, with trends toward micro‑engineered tip geometries, integrated safety mechanisms, and smart‑sensor feedback loops that improve diagnostic yield. On the demand–supply balance, demand outpaces supply in high‑growth regions (Asia‑Pacific, Middle East) as capacity expansions lag behind rapid adoption. Key risk factors include regulatory delays, raw‑material price volatility, and potential substitute technologies such as liquid biopsy platforms. Stakeholders should monitor these levers to capitalize on sustained growth.

12 items

1. Executive Summary

2. Soft Tissue Puncture Biopsy Needle Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Soft Tissue Puncture Biopsy Needle Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Soft Tissue Puncture Biopsy Needle Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Soft Tissue Puncture Biopsy Needle Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Soft Tissue Puncture Biopsy Needle Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Soft Tissue Puncture Biopsy Needle Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Soft Tissue Puncture Biopsy Needle Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Soft Tissue Puncture Biopsy Needle Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Soft Tissue Puncture Biopsy Needle Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Soft Tissue Puncture Biopsy Needle Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Soft Tissue Puncture Biopsy Needle Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Soft Tissue Puncture Biopsy Needle Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Soft Tissue Puncture Biopsy Needle Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Soft Tissue Puncture Biopsy Needle Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Soft Tissue Puncture Biopsy Needle Market Competition by Key Manufacturers

9.1. Global Soft Tissue Puncture Biopsy Needle Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Soft Tissue Puncture Biopsy Needle: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. BD

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Mammotome

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Medtronic

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Merit Medical Systems

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Cook

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Boston Scientific

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Olympus

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. ConMed

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Micro-tech

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. KDL

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Medax

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Sterylab

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Hologic

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. Weigao

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

10.15. Puang Medical

10.15.1. Company Basic Information and Sales Area

10.15.2. Main Business/Business Overview

10.15.3. Product Portfolio

10.15.4. Financial

10.15.5. Recent Industry Insights

10.15.6. SWOT Analysis

10.16. Shanghai Aisiai

10.16.1. Company Basic Information and Sales Area

10.16.2. Main Business/Business Overview

10.16.3. Product Portfolio

10.16.4. Financial

10.16.5. Recent Industry Insights

10.16.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Soft Tissue Puncture Biopsy Needle Market

Figure 4: Global Soft Tissue Puncture Biopsy Needle Market: Drivers

Figure 5: Global Soft Tissue Puncture Biopsy Needle Market: Challenges

Figure 6: Global Soft Tissue Puncture Biopsy Needle Market: Trends

Figure 7: Global Soft Tissue Puncture Biopsy Needle Market: Opportunity

Figure 8: Global Soft Tissue Puncture Biopsy Needle Market: Restraint

Figure 9: Global Soft Tissue Puncture Biopsy Needle Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Soft Tissue Puncture Biopsy Needle Market Value (USD Million) By Region

Figure 19: Global Soft Tissue Puncture Biopsy Needle Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Soft Tissue Puncture Biopsy Needle Market Value (USD Million) By Region

Figure 27: Global Soft Tissue Puncture Biopsy Needle Market Share (%) By: Regions (2032)

Figure 28: Global Soft Tissue Puncture Biopsy Needle Market Volume (K) By Region

Figure 29: Global Soft Tissue Puncture Biopsy Needle Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Soft Tissue Puncture Biopsy Needle Market Value (USD Million) By Region

Figure 37: Global Soft Tissue Puncture Biopsy Needle Market Share (%) By: Regions (2032)

Figure 38: Global Soft Tissue Puncture Biopsy Needle Market Volume (K) By Region

Figure 39: Global Soft Tissue Puncture Biopsy Needle Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

127 items

Table 1: Market Segmentation Analysis

Table 2: Global Soft Tissue Puncture Biopsy Needle Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Soft Tissue Puncture Biopsy Needle Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Soft Tissue Puncture Biopsy Needle Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Soft Tissue Puncture Biopsy Needle Market Value (USD Million) By Region

Table 14: Global Soft Tissue Puncture Biopsy Needle Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Soft Tissue Puncture Biopsy Needle Market Volume (K) By Region

Table 31: Global Soft Tissue Puncture Biopsy Needle Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Soft Tissue Puncture Biopsy Needle Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Soft Tissue Puncture Biopsy Needle Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Soft Tissue Puncture Biopsy Needle Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: BD Basic Information And Sales Area

Table 52: BD. Products Portfolio

Table 53: Mammotome Basic Information And Sales Area

Table 54: Mammotome. Products Portfolio

Table 55: Medtronic Basic Information And Sales Area

Table 56: Medtronic. Products Portfolio

Table 57: Merit Medical Systems Basic Information And Sales Area

Table 58: Merit Medical Systems. Products Portfolio

Table 59: Cook Basic Information And Sales Area

Table 60: Cook. Products Portfolio

Table 61: Boston Scientific Basic Information And Sales Area

Table 62: Boston Scientific. Products Portfolio

Table 63: Olympus Basic Information And Sales Area

Table 64: Olympus. Products Portfolio

Table 65: ConMed Basic Information And Sales Area

Table 66: ConMed. Products Portfolio

Table 67: Micro-tech Basic Information And Sales Area

Table 68: Micro-tech. Products Portfolio

Table 69: KDL Basic Information And Sales Area

Table 70: KDL. Products Portfolio

Table 71: Medax Basic Information And Sales Area

Table 72: Medax. Products Portfolio

Table 73: Sterylab Basic Information And Sales Area

Table 74: Sterylab. Products Portfolio

Table 75: Hologic Basic Information And Sales Area

Table 76: Hologic. Products Portfolio

Table 77: Weigao Basic Information And Sales Area

Table 78: Weigao. Products Portfolio

Table 79: Puang Medical Basic Information And Sales Area

Table 80: Puang Medical. Products Portfolio

Table 81: Shanghai Aisiai Basic Information And Sales Area

Table 82: Shanghai Aisiai. Products Portfolio

Table 83: Global Market Value (USD Million) (2025-2032) By Application

Table 84: Global Market Share (%) By Application (2032)

Table 85: Global Market Value (USD Million) (2025-2032) By Types

Table 86: Global Market Share (%) By Types (2032)

Table 87: Global Market Volume (K) (2025-2032) By Application

Table 88: Global Market Share (%) By Application (2032)

Table 89: Global Market Volume (K) (2025-2032) By Types

Table 90: Global Market Share (%) By Types (2032)

Table 91: Global Soft Tissue Puncture Biopsy Needle Market Value (USD Million) By Region

Table 92: Global Soft Tissue Puncture Biopsy Needle Market Share (%) By Region (2025-2032)

Table 93: North America Market Value (USD Million) (2025-2032) By Country

Table 94: North America Market Value (USD Million) (2025-2032) By Application

Table 95: North America Market Value (USD Million) (2025-2032) By Types

Table 96: Europe Market Value (USD Million) (2025-2032) By Country

Table 97: Europe Market Value (USD Million) (2025-2032) By Application

Table 98: Europe Market Value (USD Million) (2025-2032) By Types

Table 99: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 100: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 101: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 102: South America Market Value (USD Million) (2025-2032) By Country

Table 103: South America Market Value (USD Million) (2025-2032) By Application

Table 104: South America Market Value (USD Million) (2025-2032) By Types

Table 105: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 106: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 107: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 108: Global Soft Tissue Puncture Biopsy Needle Market Volume (K) By Region

Table 109: Global Soft Tissue Puncture Biopsy Needle Market Share (%) By Region (2025-2032)

Table 110: North America Market Volume (K) (2025-2032) By Country

Table 111: North America Market Volume (K) (2025-2032) By Application

Table 112: North America Market Volume (K) (2025-2032) By Types

Table 113: Europe Market Volume (K) (2025-2032) By Country

Table 114: Europe Market Volume (K) (2025-2032) By Application

Table 115: Europe Market Volume (K) (2025-2032) By Types

Table 116: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 117: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 118: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 119: South America Market Volume (K) (2025-2032) By Country

Table 120: South America Market Volume (K) (2025-2032) By Application

Table 121: South America Market Volume (K) (2025-2032) By Types

Table 122: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 123: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 124: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 125: Research Programs/Design For This Report

Table 126: Key Data Information From Secondary Sources

Table 127: Key Data Information From Primary Sources

FAQs

1. What is the current Soft Tissue Puncture Biopsy Needle market size?

The Soft Tissue Puncture Biopsy Needle market size reached roughly USD 1.2 billion in 2023, reflecting steady demand from oncology diagnostics, interventional radiology, and pathology labs worldwide. Growth drivers include rising cancer incidence and expanding minimally invasive procedure adoption.

2. What is the projected growth rate and future outlook for the market?

Analysts forecast a compound annual growth rate of about 5.5 % from 2024 through 2032, pushing the market to exceed USD 1.9 billion by 2032. The future outlook is reinforced by advances in needle design and broader reimbursement coverage.

3. Which factors are driving market expansion?

Key drivers include rising global cancer prevalence, an aging patient base demanding less invasive diagnostics, and continuous innovation such as ultra‑thin gauge needles and integrated imaging guidance. Reimbursement expansions in major economies also accelerate adoption across hospitals and outpatient centers.

4. What challenges could impede market growth?

Challenges comprise stringent regulatory approvals that prolong product launch, higher cost of advanced needle systems limiting uptake in price‑sensitive regions, and the need for specialized clinician training. Additionally, competition from alternative biopsy technologies creates pressure on pricing and market share.

5. Which regions lead the Soft Tissue Puncture Biopsy Needle market?

North America remains the largest market, driven by high healthcare spending and early technology adoption. Europe follows, with strong reimbursement frameworks, while Asia‑Pacific exhibits the fastest growth, propelled by expanding cancer screening programs and rising private hospital investments.

6. Who are the top companies competing in this market?

Leading companies include Becton Dickinson, Medtronic, Abbott Laboratories, Boston Scientific, and Teleflex. These firms differentiate through proprietary needle coatings, integrated imaging compatibility, and extensive distribution networks that support global hospital and ambulatory care customers.

7. What future opportunities are emerging for the market?

Future opportunities arise from AI‑driven imaging guidance that improves targeting accuracy, personalized medicine requiring precise tissue sampling, and untapped markets in Latin America and Africa where cancer detection infrastructure is expanding. Collaborative R&D with diagnostic firms also fuels growth.

8. How is technology shaping the Soft Tissue Puncture Biopsy Needle market?

Advances such as ultra‑sharp bevel tips, polymer‑coated shafts, and real‑time ultrasound or CT navigation are reshaping the market. Robotics‑assisted platforms further reduce operator variability, while digital connectivity enables procedure analytics and post‑procedure quality monitoring.

9. What is the regulatory landscape for these biopsy needles?

Regulatory oversight involves FDA Class II clearance in the United States, CE Mark conformity under the EU Medical Device Regulation, and ISO 13485 certification for quality management. Emerging jurisdictions are aligning with these standards, though local clinical data requirements can extend approval timelines.

Contact for Full Report

Loading report content...

Soft Tissue Puncture Biopsy Needle Market Comprehensive Report: 200+ Pages | 2026–2034

Market Snapshot

Soft Tissue Puncture Biopsy Needle Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Soft Tissue Puncture Biopsy Needle Segmentation

Soft Tissue Puncture Biopsy Needle Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Soft Tissue Puncture Biopsy Needle market size?

2. What is the projected growth rate and future outlook for the market?

3. Which factors are driving market expansion?

4. What challenges could impede market growth?

5. Which regions lead the Soft Tissue Puncture Biopsy Needle market?

6. Who are the top companies competing in this market?

7. What future opportunities are emerging for the market?

8. How is technology shaping the Soft Tissue Puncture Biopsy Needle market?

9. What is the regulatory landscape for these biopsy needles?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Soft Tissue Puncture Biopsy Needle Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Soft Tissue Puncture Biopsy Needle Segmentation

Soft Tissue Puncture Biopsy Needle Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Soft Tissue Puncture Biopsy Needle market size?

2. What is the projected growth rate and future outlook for the market?

3. Which factors are driving market expansion?

4. What challenges could impede market growth?

5. Which regions lead the Soft Tissue Puncture Biopsy Needle market?

6. Who are the top companies competing in this market?

7. What future opportunities are emerging for the market?

8. How is technology shaping the Soft Tissue Puncture Biopsy Needle market?

9. What is the regulatory landscape for these biopsy needles?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation